Assuntos
Doenças Ósseas Metabólicas/patologia , Linfoma de Zona Marginal Tipo Células B/diagnóstico , Linfoma Cutâneo de Células T/patologia , Ossificação Heterotópica/patologia , Dermatopatias Genéticas/patologia , Neoplasias Cutâneas/patologia , Doenças Ósseas Metabólicas/diagnóstico , Doenças Ósseas Metabólicas/etiologia , Vermelho Congo/metabolismo , Feminino , Humanos , Linfoma de Zona Marginal Tipo Células B/complicações , Pessoa de Meia-Idade , Ossificação Heterotópica/diagnóstico , Ossificação Heterotópica/etiologia , Dermatopatias Genéticas/diagnóstico , Dermatopatias Genéticas/etiologia , Coloração e Rotulagem/métodos , Sindecana-1/metabolismoRESUMO
PURPOSE OF REVIEW: The most recent recommendations for the management of both acute (ARS) and chronic rhinosinusitis (CRS) based on the strongest data available for each treatment modality are summarized in this review. The clinical relationships between CRS and its comorbidities are also discussed. RECENT FINDINGS: The most promising advances in rhinosinusitis management involve the use of mAbs (anti-IgE, anti-IL-5, anti-IL-4Rα) in trials of CRS with nasal polyposis. Otherwise, the mainstays of treatment for both ARS and CRS have largely remained the same over the past several years. SUMMARY: The treatment of ARS primarily involves symptomatic control with intranasal corticosteroids and nasal saline irrigation; antibiotics should be reserved for the patients who are believed to have bacterial rhinosinusitis. Treating CRS effectively involves using intranasal corticosteroids and irrigation, systemic corticosteroids, and potentially systemic antibiotics. Biologics (mAbs) have shown benefit in clinical studies. Providers should also be aware of concomitant disease processes that may afflict patients with CRS.
